RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||US$34.22|
|52 Week High||US$14.63|
|52 Week Low||US$43.26|
|1 Month Change||7.21%|
|3 Month Change||-1.24%|
|1 Year Change||21.31%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||163.23%|
Recent News & Updates
|RAPT||US Biotechs||US Market|
Return vs Industry: RAPT underperformed the US Biotechs industry which returned 28.4% over the past year.
Return vs Market: RAPT underperformed the US Market which returned 36.2% over the past year.
Stable Share Price: RAPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: RAPT's weekly volatility has decreased from 20% to 7% over the past year.
About the Company
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company’s lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
RAPT Therapeutics Fundamentals Summary
|RAPT fundamental statistics|
Is RAPT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RAPT income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.41|
|Net Profit Margin||-1,219.06%|
How did RAPT perform over the long term?See historical performance and comparison
Is RAPT Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RAPT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RAPT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RAPT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: RAPT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RAPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RAPT is overvalued based on its PB Ratio (4.6x) compared to the US Biotechs industry average (3.2x).
How is RAPT Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAPT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RAPT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RAPT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RAPT's revenue (81.8% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: RAPT's revenue (81.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RAPT is forecast to be unprofitable in 3 years.
How has RAPT Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RAPT is currently unprofitable.
Growing Profit Margin: RAPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RAPT is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.
Accelerating Growth: Unable to compare RAPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: RAPT has a negative Return on Equity (-27.57%), as it is currently unprofitable.
How is RAPT Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: RAPT's short term assets ($228.0M) exceed its short term liabilities ($10.4M).
Long Term Liabilities: RAPT's short term assets ($228.0M) exceed its long term liabilities ($3.1M).
Debt to Equity History and Analysis
Debt Level: RAPT is debt free.
Reducing Debt: RAPT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RAPT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: RAPT has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 11% each year.
What is RAPT Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RAPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RAPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RAPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RAPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RAPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brian Wong (49 yo)
Dr. Brian Russell Wong, M.D., Ph.D. has been Chief Executive Officer and Director at RAPT Therapeutics, Inc. since August 2015 and has been its President since June 2019. Dr. Wong served as a Head of Immun...
CEO Compensation Analysis
Compensation vs Market: Brian's total compensation ($USD3.57M) is above average for companies of similar size in the US market ($USD2.35M).
Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.
Experienced Management: RAPT's management team is considered experienced (2.3 years average tenure).
Experienced Board: RAPT's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RAPT insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.5%.
RAPT Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: RAPT Therapeutics, Inc.
- Ticker: RAPT
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.027b
- Shares outstanding: 29.49m
- Website: https://www.rapt.com
Number of Employees
- RAPT Therapeutics, Inc.
- 561 Eccles Avenue
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:07|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.